Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement
Pembro + CRT in HNSCC fails to deliver statistically significant event-free survival improvement
Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma
New era of early cancer detection blood tests on the horizon
Hyperthermic intraperitoneal chemo for locally advanced colon cancer
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update
HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan
Extended adjuvant AI not advised for HPBC after 5+ yrs of sequential endocrine therapy
Prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19
Olaparib continues to show positive results in advanced ovarian cancer - 7 year data
How air pollution may trigger lung cancer in never-smokers
Tumour-infiltrating lymphocyte treatment for advanced melanoma
Nirogacestat success for desmoid tumours